It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17 22:51

Henan Lingrui Pharmaceutical plans to acquire Silver Valley Pharmaceutical for 0.782 billion, entering the market of traditional Chinese medicine plaster agents as a leading player in crossover pharmaceutical markets. | Quick summary announcement.

① Henan Lingrui Pharmaceutical plans to acquire all equity of Yingu Pharmaceutical for 0.782 billion yuan, entering the chemical and innovative drugs market. ② According to data from MoShang Pharmaceuticals, Yingu Pharmaceutical's sales exceeded 0.4 billion yuan in 2023, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of the Class 1 new drug Bilitin is relatively fast. ③ If the acquisition of Yingu Pharmaceutical proceeds smoothly, the difficulty of achieving the previously set stock-based incentive unlock goals may be significantly reduced.

cls.cnDec 4 23:07

beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research

① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.

cls.cnNov 30 22:42

Henan Lingrui Pharmaceutical disclosed a stock-based incentive plan. Unlocking conditions: annual average double-digit growth in non-net income. | Speed read announcement

Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, with slightly lowered performance assessment targets compared to the previous incentive plan, but still maintaining double-digit non-GAAP performance assessment requirements. In addition to Henan Lingrui Pharmaceutical, Tibet Cheezheng Tibetan Medicine has also announced an employee stock ownership plan with high performance targets, and the industry expects bone health to be a high-potential product category in the outpatient market.

cls.cnNov 29 23:25

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

Is Guangxi Wuzhou Zhongheng Group planning to sell the controlling stake of Chongqing Lummy Pharmaceutical after years of consecutive losses? | Quick read announcement

①Guangxi Wuzhou Zhongheng Group intends to transfer the shares held directly in Chongqing Lummy Pharmaceutical through public solicitation, and the controlling shareholder and actual controller of the latter may change. ②The story of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019 and became a major shareholder of Chongqing Lummy Pharmaceutical in April of the following year, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical since then. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous loss-making state.

cls.cnNov 26 22:55